Tesevatinib - Symphony Evolution

Drug Profile

Tesevatinib - Symphony Evolution

Alternative Names: KD-019; KD-020; Tesevatinib tosylate; XL-647

Latest Information Update: 12 Sep 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Exelixis
  • Developer Exelixis; Kadmon Pharmaceuticals
  • Class Amines; Antineoplastics; Cyclopentanes; Pyrroles; Quinazolines; Small molecules
  • Mechanism of Action Protein tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Non-small cell lung cancer; Autosomal recessive polycystic kidney disease
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Non-small cell lung cancer
  • Phase II Autosomal dominant polycystic kidney disease; Glioblastoma
  • Phase I Autosomal recessive polycystic kidney disease
  • No development reported Breast cancer; Liver cancer; Prostate cancer

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 12 Sep 2017 No development reported - Phase-I/II for Breast cancer (Combination therapy, Metastatic disease, Second-line therapy or greater) in USA (PO) (Kadmon pipeline September 2017)
  • 09 Aug 2017 Kadmon Corporation initiates enrolment in a phase II trial for Autosomal-dominant polycystic kidney disease in USA (PO) (NCT03203642)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top